Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04556318 |
Recruitment Status :
Completed
First Posted : September 21, 2020
Last Update Posted : July 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Breath analysis is the evaluation of exhaled air of humans. It aims to get information about the clinical status of a human being by monitoring its volatile organic compounds (VOCs) in exhaled air.
In this feasibility study it is intended to find specific biomarker(s) in exhaled breath indicating an infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
Condition or disease | Intervention/treatment |
---|---|
Covid19 | Device: Ion Mobility Spectrometry (IMS) |
Study Type : | Observational |
Actual Enrollment : | 396 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2 |
Actual Study Start Date : | September 23, 2020 |
Actual Primary Completion Date : | June 11, 2021 |
Actual Study Completion Date : | June 11, 2021 |

- Device: Ion Mobility Spectrometry (IMS)
Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
- SARS-CoV-2 related volatile organic compounds (VOC) [ Time Frame: 1 hour after breath gas sampling ]
- To compare the SARS-CoV-2 specific VOC with the clinical symptoms of COVID-19 and diagnostic findings [ Time Frame: Within 3 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- SARS-CoV-2-Polymerase chain reaction (PCR) test result is available
- Signs or symptoms of any respiratory system infection or Signs or symptoms indicating SARS-CoV-2 infection or Radiological findings suggesting viral lung infection
- Breath test (Study intervention) must be performed within a 2 day time period after latest SARS-CoV-2 PCR
Exclusion Criteria:
- History of SARS-CoV-2 outside the current respiratory episode (known from medical history)
- Participation in another clinical study prior to breath analysis which could influence the result of the breath analysis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04556318
Germany | |
Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin | |
Berlin, Germany | |
Technical University of Munich, Klinikum rechts der Isar | |
Munich, Germany |
Principal Investigator: | Christoph Spinner, PD Dr. | Technical University of Munich, Klinikum rechts der Isar |
Responsible Party: | B. Braun Melsungen AG |
ClinicalTrials.gov Identifier: | NCT04556318 |
Other Study ID Numbers: |
HC-N-H-2004 |
First Posted: | September 21, 2020 Key Record Dates |
Last Update Posted: | July 8, 2021 |
Last Verified: | July 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |